Rigosertib(acid)

Rigosertib(acid) - Names and Identifiers

Name	(2-METHOXY-5-[2-(2,4,6-TRIMETHOXY-PHENYL)-ETHENESULFONYLMETHYL]-PHENYLAMINO)-ACETIC ACID, SODIUM SALT
Synonyms	CS-1407 Rigosertib Rigosertib(acid) (E)-2-((2-Methoxy-5-(((2,4,6-triMethoxystyryl)sulfonyl)Methyl)phenyl)aMino)acetic acid N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl]methyl]phenyl]glycine Glycine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]- (2-METHOXY-5-[2-(2,4,6-TRIMETHOXY-PHENYL)-ETHENESULFONYLMETHYL]-PHENYLAMINO)-ACETIC ACID, SODIUM SALT
CAS	592542-59-1

Rigosertib(acid) - Physico-chemical Properties

Molecular Formula	C21H25NO8S
Molar Mass	451.49
Density	1.332±0.06 g/cm3(Predicted)
Melting Point	172-174 °C(Solv: acetone (67-64-1))
Boling Point	756.1±60.0 °C(Predicted)
pKa	4.23±0.20(Predicted)
Storage Condition	Room Temprature

Rigosertib(acid) - Reference Information

introduction

reegerase is an ATP non-competitive PLK1 inhibitor with an IC50 value of 9 nM and a selectivity of more than 30 times that of PLK2. it is a synthetic benzylstyrene sulfone developed by OnCONOVA therapy and is a phase III clinical trial for the treatment of chronic myelomonocytic leukemia.

Last Update：2024-04-09 19:05:04